Results 11 to 20 of about 367,353 (219)

Clear Cell Renal Cell Carcinoma [PDF]

Radiopaedia.org, 2020
These are also called as Environmental cells; these are having a pale appearance, with 70% individuals and renal cell cancer, the growth of this type of cell are either be fast or be slow.
null Sarah Bastawrous, null John W. Rago, MD, null Lisa N. Johnson, MD   +2 more
semanticscholar   +7 more sources

Clear Cell Renal Cell Carcinoma

Mayo Clinic Proceedings, 2018
Hamish Smith, Yuranga Weerakkody, Rohit Sharma   +2 more
semanticscholar   +7 more sources

Metabolic reprogramming of clear cell renal cell carcinoma

Frontiers in Endocrinology, 2023
Clear cell renal cell carcinoma (ccRCC) is a malignancy that exhibits metabolic reprogramming as a result of genetic mutations. This reprogramming accommodates the energy and anabolic needs of the cancer cells, leading to changes in glucose, lipid, and ...
Haiyan Zhu, Xin Wang, Shihao Lu, Kongbo Ou   +3 more
doaj   +2 more sources

Clear cell renal cell carcinoma

Radiopaedia.org, 2014
Vikas Shah, Bruno Paulino Di Muzio
semanticscholar   +4 more sources

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2022
BACKGROUND The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence.
T. Powles, P. Tomczak, S. Park, B. Venugopal, T. Ferguson, S. Symeonides, J. Hajek, H. Gurney, Yen‐Hwa Chang, Jae Lyun Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. Haas, P. Sawrycki, J. Burgents, Lei Xu, K. Imai, D. Quinn, T. Choueiri, T. Choueiri, Thomas Ferguson, Tzu-Ping Lin, S. Symeonides, N. Haas, H. Gurney, C. Chevreau, J. Burke, G. Doshi, B. Melichar, D. Topart, S. Oudard, Evgeniy Kopyltsov, H. Hammers, D. Quinn, A. Alva, J. Menezes, A. G. Silva, E. Winquist, A. Hamzaj, G. Procopio, B. Karaszewska, E. Nowakowska-Zajdel, B. Alekseev, R. Gafanov, A. Izmailov, A. Semenov, S. Afanasyev, O. Lipatov, T. Powles, S. Srinivas, D. McDermott, S. Kochuparambil, I. Davis, K. Peltola, R. Sabbatini, Jinsoo Chung, M. Shkolnik, V. Matveev, P. Gajate Borau, S. McCune, Thomas E. Hutson, A. Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, P. Bostrom, B. Laguerre, C. Buttigliero, U. de Giorgi, E. Fomin, Y. Zakharia, C. Hwang, E. Singer, J. Yorio, D. Waterhouse, R. Kowalyszyn, M. Alfie, Eduardo Yañez Ruiz, T. Buchler, Krista Kankaanranta, G. Ferretti, G. Kimura, K. Nishimura, N. Masumori, S. Tamada, H. Kato, H. Kitamura, I. Danielewicz, J. Wójcik-Tomaszewska, N. Sala González, K. Chiu, M. Atkins, E. Heath, G. Rojas-Uribe, M. González Fernández, S. Feyerabend, S. Pignata, K. Numakura, Bożena Cybulska Stopa, R. Zukov, M. A. Climent Duran, P. Maroto Rey, A. Montesa Pino, Chao‐Hsiang Chang, S. Vengalil, T. Waddell, P. Cobb, R. Hauke, Daniel M Anderson, J. Sarantopoulos, T. Gourdin, Tian Zhang, G. Jayram, L. Fein, C. Harris, P.M.M. Beato, F. Flores, Á. Estay, J. Rubiano, J. Bedke, S. Hauser, A. Neisius, J. Busch, S. Anai, H. Tsunemori, Dariusz Sawka, Bożena Sikora-Kupis, J. Arranz, I. Delgado, C.-H. Chen, E. Gunderson, S. Tykodi, A. Koletsky, Kevin Chen, M. Agrawal, D. Kaen, J. P. Sade, M. Tatangelo, F. Parnis, Fernando Maciel Barbosa, G. Faucher, N. Iqbal, D. Marceau, Jean-Benoît Paradis, N. Hanna, Alejandro Acevedo, C. Ibáñez, L. Villanueva, Pedro Pablo Galaz, I. Durango, R. Manneh, Z. Král, P. Holečková, H. Hakkarainen, H. Ronkainen, S. Abadie-Lacourtoisie, S. Tartas, P. Goebell, M. Grimm, T. Hoefner, M. Wirth, A. Panic, W. Schultze‐Seemann, A. Yokomizo, R. Mizuno, H. Uemura, M. Eto, M. Tsujihata, Y. Matsukawa, Y. Murakami, Miso Kim, P. Hamberg, Malgorzata Marczewska-Skrodzka, C. Szczylik, A. Humphreys, Peter Jiang, Birendra Kumar, G. Lu, A. Desai, J. Karam, G. Keogh, M. Fleming, J. Zarbá, Viviana E. Leiva, G. Mendez, Samuel J. Harris, Stephen J. Brown, Joao Neif Antonio Junior, Rita de Cassia Costamilan, R. O. Rocha, D. Muniz, L. Brust, Aly-Khan A. Lalani, J. Graham, M. Levesque, F. Orlandi, R. Kotásek, J. Deville, D. Borchiellini, A. Merseburger, M. Rink, F. Roos, Raymond J. McDermott, M. Oyama, Yoshiaki Yamamoto, Y. Tomita, Yuji Miura, N. Ioritani, Hans Westgeest, T. Kubiatowski, W. Bal, R. Gironés Sarrió, Juliet M. Rowe, D. Prow, F. Senecal, N. Hashemi-Sadraei, S. Cole, S. Kendall, D. Richards, I. Schnadig, M. Gupta   +222 more
semanticscholar   +1 more source

Oncogenic microRNAs characterization in clear cell renal cell carcinoma [PDF]

, 2015
A key challenge for the improvement of clear cell renal cell carcinoma (ccRCC) management could derive from a deeper characterization of the biology of these neoplasms that could greatly improve the diagnosis, prognosis and treatment choice. The aim of
BELLISSIMO, TERESA, CARBONE, Antonio, DELLA ROCCA, Carlo, DI CARLO, ANGELINA, FAZI, Francesco, PALLESCHI, GIOVANNI, PASTORE, ANTONIO LUIGI, PETROZZA, Vincenzo, PORTA, NATALE   +8 more
core   +2 more sources

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Journal of Clinical Oncology, 2022
PURPOSE To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non–clear-cell renal cell carcinoma (RCC).
Chung-Han Lee, M. Voss, M. Carlo, Ying-bei Chen, M. Zucker, A. Knezevic, R. Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J. Shah, C. Owens, D. McHugh, D. Aggen, A. Laccetti, R. Kotecha, D. Feldman, R. Motzer   +17 more
semanticscholar   +1 more source

Clinical utility of MCM2 and CD44 expression in clear cell renal cell carcinoma

Polish Journal of Pathology, 2021
Clear cell renal cell carcinoma (ccRCC) has an unpredictable clinical consequence even with the use of usual prognostic factors. To determine whether utilization of cell proliferation and cell adhesion by using MCM2 and CD44 immuno-expression could ...
Mariana F. Gayyed, Medhat M. Soliman, Maram El-Hussieny   +2 more
doaj   +1 more source

A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression

International Journal on Biological Sciences, 2022
Inactive von Hippel-Lindau (VHL) is linked to metabolic reprogramming and plays pivotal roles in the pathogenesis of clear cell renal cell carcinoma (ccRCC).
Jiefeng Yang, Li Luo, Chongyu Zhao, Xiyuan Li, Zimo Wang, Z. Zeng, Xin Yang, Xiaobin Zheng, H. Jie, Liang Kang, Shujuan Li, Shuang Liu, Chi Zhou, Huashan Liu   +13 more
semanticscholar   +1 more source

Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature

Urology Case Reports, 2018
Clear cell renal cell carcinoma and papillary renal cell carcinoma are the most common types of renal tumors. However, coexistence of both tumors in the same kidney is a rare condition.We report a 56-year old male who was found to have ipsilateral ...
Muna Alhusban, Sohaib Alhamss, Bayan Alzumaili, Ali Al-Daghmin   +3 more
doaj   +1 more source